Fulcrum Therapeutics to Merge with Slate Medicines; Plans $275M Dividend

Fulcrum Therapeutics, Inc. has entered into a merger agreement with Slate Medicines, Inc., with the transaction expected to close in the fourth quarter of 2026, pending stockholder approval and other conditions. The company also plans to declare a cash dividend of $275 million to its pre-Merger stockholders. In preparation for the merger, Fulcrum has ceased development of its pociredir program and implemented a significant restructuring, including an 85% workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and had $306.5 million in cash, cash equivalents, and marketable securities as of that date.